维瓦尼医疗公司的微型化物植入物用于治疗肥胖症显示,小鼠体重减轻了20%,肝脏脂肪减少了82%,等待2024年第一阶段试验. Vivani Medical's mini exenatide implant for obesity treatment shows 20% weight loss and 82% liver fat reduction in mice, awaiting Phase 1 trial in 2024.
Vivani Medical, Inc. 宣布其为治疗肥胖症而植入的微型减肥植入物的临床预科结果大有希望。 Vivani Medical, Inc. announced promising preclinical results for its miniature exenatide implant aimed at obesity treatment. 在对肥胖小鼠的研究中,植入物在28天后体重减少了20%,肝脂肪减少了82%。 In studies with obese mice, the implant achieved a 20% weight loss and an 82% reduction in liver fat after 28 days. 美国食品和药物管理局已经批准了Vivani的植入物新药研究申请,使即将开始的LIBERATE-1第一阶段试验能够在2024年底开始,预计结果将在2025年发布. The FDA has cleared Vivani's Investigational New Drug Application for the implant, enabling the upcoming LIBERATE-1 Phase 1 trial expected to start in late 2024, with results anticipated in 2025.